From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma

Vladimir Ratushny, Michael D. Gober, Ryan Hick, Todd W. Ridky, and John T. Seykora

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Cutaneous squamous cell carcinoma (cSCC) is the second most common human cancer with over 250,000 new cases annually in the US and is second in incidence only to basal cell carcinoma. cSCC typically manifests as a spectrum of progressively advanced malignancies, ranging from a precursor actinic keratosis (AK) to squamous cell carcinoma (SCC) in situ (SCCIS), invasive cSCC, and finally metastatic SCC. In this Review we discuss clinical and molecular parameters used to define this range of cutaneous neoplasia and integrate these with the multiple experimental approaches used to study this disease. Insights gained from modeling cSCCs have suggested innovative therapeutic targets for treating these lesions.

Introduction

Actinic keratoses (AKs) are likely the most common keratinocyte-derived precancerous lesion in humans; they are found predominantly in fair-skinned individuals on sun-exposed surfaces (1, 2). The primary risk factor for AKs is cumulative UV exposure from sunlight and/or tanning salons, and it is expected that the incidence of AKs will rise given an aging US population (3–5). AKs are frequently found in skin harboring fully developed cutaneous squamous cell carcinomas (cSCCs) (6). AKs progress to cSCC at a rate estimated between 0.025% and 16% for an individual lesion per year (7, 8). The typical patient has 6 to 8 lesions; therefore, a rate estimated between 0.025% and 16% for an individual lesion per year (7, 8). The typical patient has 6 to 8 lesions; therefore, a patient with multiple AKs has a annual risk of developing invasive squamous cell carcinoma (SCC) ranging from 0.15% to 80% (2, 3, 6, 7). This wide range in risk reflects a lack of precision in our knowledge of the progression of carcinoma in the epidermis. It is estimated that approximately 26% of AKs will undergo regression over a year’s span (8). The probability of an AK or a patient with multiple AKs developing a cSCC or metastatic lesion is shown in Figure 1 (9, 10).

AKs are defined at the histologic level by dysplasia and consist of keratinocytes manifesting atypical nuclei that are enlarged, irregular, and hyperchromatic. AKs also display disorganized growth, which disrupts differentiation and results in a thickened stratum corneum with retained nuclei. To stratify degrees of epidermal dysplasia, a three-tiered grading scale has been proposed for AKs that parallels that used for evaluation of cervical dysplasia (11). The histological features of keratinocytic intraepidermal neoplasia I (KIN I) are cellular atypia of basal keratinocytes confined to the lower third of the epidermis. KIN II shows atypical keratinocytes occupying the lower two-thirds of the epidermis, and KIN III shows atypical keratinocytes throughout the epidermis; this latter stage is equivalent to carcinoma in situ (11). The localized epidermal atypia in AKs reflects a partial disruption of the differentiation program, whereas a more complete disruption of differentiation is associated with SCC in situ (SCCIS). The regression rate of AKs may be inversely related to their degree of dysplasia, as has been seen in vaginal epithelium (12). While the KIN grading criteria evaluate the macroscopic and microscopic features of AKs, identification of genetic and molecular abnormalities associated with these lesions has provided mechanistic insight into their pathogenesis (Figure 2).

The classic multistep model of carcinogenesis is useful for understanding the progression from AK to cSCC (13). According to this model, mutations in one gene, often a tumor suppressor, may lead to the development of a precursor lesion with increased genetic instability or loss of cell cycle control. Additional mutations in other driver oncogenes permit the emergence of more neoplastic properties, leading to invasive carcinoma; the number of genetic changes required to transition from benign epithelium to metastatic carcinoma internal malignancies is thought to range from four to six (13). However, 3D models of human epidermis have shown that as few as two proto-oncogene mutations changes are sufficient to drive SCC (14, 15). An improved understanding of epigenetic regulation of oncogene and anti-oncogene expression will add layers of regulatory complexity to the multistep model of carcinogenesis.

As with other cancers, cSCC exhibits impaired genomic maintenance that facilitates acquisition of new mutations (16). The mechanism leading to genomic instability in keratinocytes likely results from UVB-induced inactivation of p53, since approximately 58% of cSCCs harbor UVB signature mutations such as CC→TT and C→T transitions (17). The role of p53 in UVB-induced carcinogenesis has been confirmed in p53−/− mice which have an increased propensity for developing AK-like lesions and cSCCs secondary to UVB exposure (18). Since the initial observations of ultraviolet-induced mutations in p53, other groups have confirmed the presence of p53 mutations in significant percentages of cSCCs (19–21).

p53 is mutated commonly in AKs, demonstrating that dysplastic lesions have acquired the initial genetic mutations prior to becoming cSCC (20, 22). Additional studies have shown a high prevalence (74%) of p53 mutations in unremarkable sun-exposed skin compared to non-sun-exposed skin (5%) (23), setting the stage for acquisition of mutations in driver oncogenes. Consistent with these findings, 40% of SCCIS harbors p53 mutations, indicating that p53 loss occurred prior to tumor invasion (24). In contrast, several internal malignancies demonstrate mutation of the p53 gene...
gene as a late event in neoplastic evolution after formation of an invasive lesion (25–27).

Aberrant activation of EGFR and Fyn, a Src-family tyrosine kinase (SFK), are seen in human cSCCs, and these kinases down-regulate p53 mRNA and protein levels through a c-Jun–dependent mechanism (28, 29), revealing another mechanism for controlling p53 function. Additional molecular events associated with AK formation include increased activation or levels of SFKs, EGFR, Myc, and ATF-3 (30–33). In addition, decreased levels of inositol polyphosphate 5′-phosphatase have also been reported in AKs, which could result in increased PI3K/Akt signaling (34).

Immunohistochemical studies of AKs to assess p53 levels have shown variable results, but many studies show increased p53 levels in lesions that are likely due to the enhanced stability of the mutant p53 proteins (35). However, more mechanistic studies are needed to link specific p53 mutations found in human AKs with altered functional status and protein stability.

Loss-of-heterozygosity studies of AKs have shown genetic alterations at the following loci: 3p, 9p, 9q, 13q, 17p, and 17q; these data indicate that substantial genomic instability is already present at the preneoplastic AK stage (36). However, the genes, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) affected by these genetic alterations have not yet been linked to mechanisms driving neoplasia.

Loss of heterozygosity has also been observed in cSCCs at chromosome 9p in 13 of 16 primary tumors (37). Loss of heterozygosity of p16, a cell cycle regulator that lies in this region, is hypothesized to be associated with progression from AKs to cSCCs (38), and loss of function of p16 is more frequent in cSCCs than in precancerous lesions (39–41). Additional loss-of-heterozygosity loci in cSCCs include 3p, 2q, 8p, and 13 and allelic gains on 3q and 8q (37).

Amplification and activating mutations of the Ras oncogene have been found in SCCs and AKs (42, 43). Of the three Ras genes, Harvey rat sarcoma virus oncogene (Hras) is preferentially mutated in the general population (44). Ras molecules are a family of GTP-binding proteins that are among the most frequently mutated genes in humans cancers (45). Ras is an upstream activator of the Raf/Mek/Erk1/Erk2 kinase pathway, and activating mutations in Ras can promote cSCC formation (45). The latest data from the catalog of somatic mutations in cancer (COSMIC; Sanger Institute) indicate that 21% of cSCCs harbor activating Ras mutations (9% Hras, 7% Nras, 5% Kras) (46). The characteristic mutations at codons 12, 13, and 61 of H-Ras are all localized opposite pyrimidine dimer sites (C-C) and likely result from UVB exposure (42).

**Role of extracellular matrix and basement membrane components in SCC**

The interactions between tumor cells with their extracellular matrix and the basement membrane zone (BMZ) are important determinants of tumorigenesis and have been shown to play a role in cSCC (47). Laminin 332 (previously known as laminin 5) is a BMZ component involved in epithelial-mesenchymal cohesion in multiple tissues including the epidermis (47). Laminin 332 and one of its ligations partners, α6β4 integrin, were shown to be required for tumorigenesis in a murine xenograft model of human SCC (14). In this model, tumor formation by human keratinocytes transformed through retrovirally mediated expression of HRAS and IκBα was completely inhibited with blocking antibodies to laminin 332 or β4 integrin. Collagen VII is a component of anchoring fibrils in the BMZ, which anchor the basement membrane to the underlying dermis. In a 3D organotypic skin model of SCC, siRNA-mediated depletion of collagen VII promoted migration, invasion, disorganized differentiation, and epithelial-mesenchymal transition (48). The 3D organotypic model has been used to define gene expression profiles in the epithelial and stromal components of tumors important for carcinogenesis (49). Expression of β1-integrins and their ligands correlates with tumor progression in human skin, so further characterization of the mitogenic signaling mechanisms between HRAS and the integrin/BMZ complex will likely increase our understanding of cSCC pathogenesis.

**Identifying the cell of origin in SCC**

In the hair follicle bulge and the basal layer of the interfollicular epidermis, epidermal stem cells have the potential for self-renewal and multi-lineage differentiation and have beenpegged as putative cells of origin for cSCC (50). In a chemical carcinogenesis model of cSCC, 7,12-dimethyl-1,2-benzanthracene (DMBA) initiated epidermal tumor formation in mice treated with 5-fluorouracil (5-FU), a compound that kills actively cycling cells in the epidermis (51). These data suggest that the tumors arose from the quiescent, 5-FU-insensitive epidermal stem cells rather than the rapidly proliferating epidermal cells. When oncogenic Hras was expressed in suprabasal cells of the mouse epidermis under the keratin 10 gene promoter, benign papillomas, a benign squamous skin tumor seen in murine
models, arose at sites of wounding (52). In contrast, when this same oncogene was expressed in the hair follicle under the control of the truncated keratin 5 gene promoter, cSCC and some spindle cell carcinomas developed in adult mice (53). Another approach to identify the cSCC cell of origin involved expressing a constitutively active mutant form of KRAS (G12D) at physiological levels in multiple epidermal compartments using a tamoxifen-inducible CRE-Lox system (54). The expression of mutated KRAS in hair follicle bulge stem cells, but not in the developmentally committed transient amplifying matrix cells, resulted in formation of papillomas. Although KRAS G12D expression alone was not sufficient to induce malignant transformation, the combination of this oncogene with a deletion of p53 in bulge stem cells induced invasive SCC, but the combination was not tumorigenic in transient amplifying matrix cells. There is also evidence that bone marrow-derived cells may home to the bulge region of the epidermis in response to skin wounding and differentiate into keratinocyte stem cells (55). These bone marrow-derived cells possess the capacity to undergo malignant transformation with persistent stimulation (i.e., chronic inflammation) in their new environment (50, 56, 57). Considering the differences in epidermal stem cells and the determinants of tumorigenesis between mice and humans, further investigation into the role of cancer propagating cells in human cSCC is warranted.

Pathophysiologic features of cSCCs. Ras family members of proto-oncogenes transduce cellular growth and proliferation signals downstream of cell membrane–bound receptor tyrosine kinases (RTKs). Ras can be activated by gene amplification, activating mutations, or overexpression of upstream RTKs. Aberrant Ras activation promotes several key tumorigenic phenotypes including mitogenesis, resistance to apoptosis, drug resistance, and angiogenesis (45). It was experimentally shown that activation of oncogenic Ras alone was not sufficient to induce SCC in human keratinocytes (58). Instead, it was necessary to couple Ras overexpression with the activation of the cell cycle progression mediator CDK4, or to modulate NF-kB activity to bypass Ras-mediated G1 arrest and induce epidermal tumorigenesis (14). NF-kB is important for growth inhibition in keratinocytes, and blockade of this pathway induces cSCC in murine experimental models (59, 60). Epidermal hyperproliferation secondary to NF-kB blockade was associated with increased CDK4 protein levels, thus linking control of the G1/S cell cycle transition to the growth regulatory functions of NF-kB (59). These experimentally produced tumors mimicked human cSCCs by demonstrating E-cadherin downregulation and induction of angioinvasive and invasive cellular factors (14, 15, 45).

Figure 2
A clinical, histologic, and molecular comparison of AKs, cSCC, and metastatic cSCC. The common clinical, histologic, and molecular features of human cutaneous neoplasia are shown.
Ras (61). In these studies, oncogenic Hras dramatically induced Fyn mRNA but not the related kinases Src or Yes (61). Fyn was required for cell invasion and motility, and Fyn also was necessary for Hras-induced activation of focal adhesion kinase (61). Hras upregulates Fyn mRNA through an Akt-dependent mechanism, and since Fyn activates the PI3K/Akt pathway, it may amplify its own expression through a positive feedback mechanism (29). These data suggest an interesting biological relationship between Ras and Fyn in cutaneous neoplasia that should be further evaluated and could be explored through topical application of small molecule kinase inhibitors (SMKIs), which are used to treat systemic cancers and have the physical properties required to penetrate skin. The ideal SMKIs would target Fyn and related tyrosine kinases or would target kinases in the Ras pathway. Inhibition of these signaling nodes could manifest chemoablative properties on AKs and cSCCs. One potential candidate is dasatinib, which is smaller than 500 daltons and targets multiple tyrosine kinases, including Fyn (62).

SFKs, including Fyn, are regulators of cell proliferation, invasion, and metastasis and have been shown to play a role in the pathogenesis of cSCC (29, 61, 63–65). Src-activating and signaling molecule (Srcasm) is a substrate and negative regulator of SFKs (66, 67). Srcasm has been shown to limit keratinocyte proliferation, promote differentiation, and negatively regulate EGFR and SFK signaling in primary human keratinocytes (68, 69). In human AKs and cSCCs, immunohistochemical studies have demonstrated that Srcasm levels are reduced compared with adjacent nonlesional epidermis (44, 68). The potency of Fyn in promoting skin tumorigenesis was confirmed in the phenotype of K14-Fyn Y528F mice (described below), which spontaneously develop precancerous lesions resembling AKs and cSCCs at five to eight weeks of age (29). Analysis of these lesions revealed activation of three pro-oncogenic signaling pathways: PDK-1/Akt/mTOR, MEK/ERK, and STAT3. Activation of these signaling pathways coupled with Fyn-induced downregulation of p53 and Notch1 represents a strong oncogenic signal that can induce spontaneous skin tumor formation even in the C57BL/6 tumor-resistant genetic background (29). Increasing Srcasm levels with a K14-Srcasm transgene completely inhibits Fyn-induced skin neoplasia. The relevance of these in vivo murine observations to human disease was demonstrated by the finding that human cSCCs demonstrate elevated Fyn and activated SFK levels coupled with decreased Srcasm levels when compared with adjacent nonlesional skin (29). These data support the hypothesis that Srcasm functions as a tumor suppressor in human cSCCs and that inhibiting SFKs or enhancing Srcasm function may be a potential therapeutic strategy for treating cutaneous neoplasia.

Recent work has shown that PKC-δ mRNA is markedly downregulated in human cSCCs compared to epidermis suggesting that decreased PKC-δ levels are important for UVB-induced neoplasia (70). Fyn phosphorlates PKC-δ, and PKC-δ is an important regulator of UVB-induced apoptosis; it will be important to determine how Fyn and Srcasm regulate PKC-δ phosphorylation and protein/mRNA levels and correlate this UVB-induced apoptosis (71, 72).

Notch signaling has been implicated in both normal epidermal development and in the pathogenesis of cSCC (73). Notch signaling regulates many important cellular processes including stem cell maintenance, cell fate decisions, differentiation, proliferation, and apoptosis (74). There are four mammalian Notch proteins; Notch1 is expressed in all the layers of the human epidermis, while Notch2 is expressed in the basilar layer (73). Notch signaling promotes keratinocyte differentiation by several mechanisms including the induction of the cell cycle inhibitor p21, and was shown to decrease proliferation and increase the differentiation of embryonic keratinocytes through the activation of caspase-3 and PKC-δ (75). In a panel of surgically excised human cSCCs, Notch1 expression was reduced in comparison with nonlesional epidermal controls (76). Notch1 is a direct transcriptional target of p53 in human keratinocytes (76), and given the frequency of

**Figure 3**

Key signaling pathways involved in the formation of cSCC. Mutations induced by UVB exposure can perturb multiple cellular pathways leading to contribute to the formation of cSCC. Thick arrows signify an increase or decrease of signaling in SCC. Red T-bars indicate inhibitory relationships.
Notch1 downregulation may be a downstream consequence of p53 alteration in these lesions. Notch1 is downregulated by EGFR and Fyn through inhibition of p53 transcription, in a mechanism that also involves activation of c-Jun (28, 29). Therefore, the oncogenic consequence of EGFR and Fyn activation includes the downregulation of p53 and Notch1. Acting as a keratinocyte tumor suppressor, Notch1 was shown to repress the tumorigenic Wnt and the Sonic hedgehog (Shh) signaling pathways in Notch1-deficient mice (74, 77). Loss of Notch1 signaling in primary human keratinocytes and murine epidermis results in aberrant activation of β-catenin, an effector of Wnt signaling. Conversely, expression of a dominant active form of Notch1 in primary keratinocytes represses β-catenin–mediated transcriptional activation and depressed β-catenin protein levels (77). Notch1 expression in the epidermis prevents the induction of SCC and BCC-like lesions in murine topical chemical carcinogenesis models. (77). Notch deficiency may inhibit DNA repair mechanisms and pro-apoptotic pathways, rendering cells more sensitive to chemical mutagens (77). Indeed, injection of nude mice with Notch1-deficient primary keratinocytes expressing activated Ras or with keratinocytes expressing activated Ras treated with a pharmacological inhibitor of Notch signaling results in the formation of poorly differentiated, highly invasive SCCs (76). These results suggest that pro-oncogenic mutations in the setting of Notch1 deficiency may enhance the malignant potential of tumors.

STAT3 belongs to a family of transcription factors that modulate a variety of target genes involved in apoptosis, angiogenesis, and cell cycle regulation. The role of STAT3 in UVB-induced cutaneous tumorigenesis was evaluated using transgenic and gene-deficient mouse models with constitutively active STAT3 expressed in the skin (K5-Stat3C) or skin-specific STAT3 deficiency (78). Following UVB exposure, the K5-Stat3C mice developed cSCCs at a greater frequency and with an increased multiplicity than control mice (78). Conversely, epidermal STAT3 deficiency protected mice from UVB tumorigenesis. The K5-STAT3 mouse epidermis had an elevated expression of antiapoptotic mediator Bcl-xL, and consequently the keratinocytes in this model were resistant to UVB-induced apoptosis (47). A diagram of the key signaling events that promote cSCC formation is shown in Figure 3.

Mouse models of SCC

Understanding human neoplasia relies on, but also has been limited by, the experimental models used to study tumor initiation and progression. Transgenic and “knockout” mice have proven to be useful in vivo models to study epidermal tumorigenesis. Transgenic expression of ErbB2, Src, Fyn, and MEK-1 kinases driven by keratin promoters in the epidermis can spontaneously produce cutaneous neoplasia leading to cSCCs (29, 64, 65, 79). K14-Fyn Y528F transgenic mice, which express an activated form of Fyn in the epidermis, produce flat precancerous lesions resembling human AKs rather than papillomas, which are seen in the classic “two-step” chemical carcinogenesis models but are not seen in human UVB-induced cutaneous neoplasia (29). These studies suggest that upregulation of the EGFR/Fyn/Src/Erk pathway appears critical for promoting cSCC formation. In support of this hypothesis, K14-ER:Ras transgenic mice, which harbor a tamoxifen-inducible Hras G12V, demonstrate a Ras-dependent epidermal hyperplasia associated with impaired differentiation resembling SCCIS (80). Other transgenic mouse lines with increased STAT3 activity also demonstrate spontaneous and UVB-induced cutaneous neoplasia leading to cSCCs (78).

Although transgenic mice are a strong in vivo model for studying cSCC formation, the inherent differences in skin structure between mice and humans limits direct correlation of murine models with human disease (Figure 4). Furthermore, there are differences in the cell signaling and functional profiles of oncogenes and tumor suppressor genes between mice and humans. For example, a component of the transforming actions of Ras are mediated through Ral activation in human cells, whereas they are mediated by Raf in murine fibroblasts (81). Therefore, correlation of experimental observations made in murine models with human tissue is key for demonstrating relevance to the human disease.
Noncoding RNAs in SCC
In addition to mutations in classic protein-coding genes, development and progression of SCC is likely influenced by alterations in specific noncoding RNA transcripts, including short, similarly structured, approximately 22-nucleotide miRNAs and long, variably structured (200-nt to 100-kb) IncRNAs. Because this field is in its relative infancy, functional mechanistic studies pertaining to these molecules are lacking in keratinocyte neoplasias. However, given their emerging importance as factors regulating both centrally acting cancer-associated pathways such as p53 in other tissues (82) and stem cell maintenance pathways in epidermis (83), it is likely that they will also serve similar functions in cSCC.
Consistent with a likely role of miRNA in cSCC development, SCC tumor tissue is associated with increased activity of Drosha, a key element required for miRNA maturation (84). Further, the miRNA profile in epidermis is altered in SCC, with both tumors and UVA-exposed keratinocytes displaying elevated levels of miR21 (85). Strong evidence supports a role for miR21 as an oncomir that suppresses tumor suppressor genes in epithelial cancers (86, 87). SCC tumors also display lower levels of miR203 (85), an antagonist of the p63 transcription factor required for the proliferation and maintenance of epidermal stem cells and upregulated in SCC.
Mdm2 is a negative regulator of p53, and the SNP309 G allele of Mdm2 is associated with a mildly increased risk of developing cSCC (88). The p53 chemotherapeutic DNA damage response includes induction of IncRNAs such as p21 associated ncRNA DNA damage activated (PANDA) that regulate p53-mediated transcription of pro-apoptotic genes such as FAS (89). However, it is not yet clear whether PANDA or other IncRNAs contribute to the p53-mediated UVB DNA damage response. There are currently no studies associating or establishing functional roles for IncRNAs in cSCC, although recent evidence does suggest that at least one such transcript whose expression is associated with worse prognosis (HOTAIR) increases the invasiveness of epithelial breast cancer cells (90). As over 90% of the genome is transcribed, with the vast majority of species noncoding, future work utilizing high-throughput complete transcriptome analysis may reveal specific IncRNAs associated with SCC, with some specific sequences or structural motifs playing important roles in cancer genesis.

Drug-induced cSCCs
There are a number of clinical situations in which increased cSCC formation in patients is associated with medical conditions and drug usage. Understanding the biological effects of these drugs on human skin yields novel in vivo insights into the biology of human cSCCs.

Organ transplant recipients. A particularly high-risk population for cSCC are organ transplant recipients (OTRs). While immunosuppressive therapy used by OTRs is critical to prevent allograft rejection, it may predispose patients to multiple side effects including, but not limited to, cutaneous infections and neoplasms (91). cSCC is the most common neoplasm in OTRs, and its risk is increased by 60- to 100-fold in this patient population in comparison with immunocompetent controls (92, 93). Two primary drugs used in the immunosuppression regimen of OTRs are azathioprine, a purine synthesis inhibitor, and cyclosporine, a calcineurin inhibitor. Azathioprine was shown to increase UVA light photosensitivity (94). Unlike UVB light, the energy transmitted by UVA light is not usually sufficient to cause direct DNA damage (93). However, UVA light can cause indirect DNA damage through oxidative stress, and azathioprine was shown to augment reactive oxygen species–induced DNA damage (94). Cyclosporine and other calcineurin inhibitors have also been shown promote tumor formation independent of their actions on the host immune system (93, 95, 96). Cyclosporine treatment promotes tumor growth in mice with SCID, which lack intact cell-mediated immunity (96). In addition, a recent study demonstrated that cyclosporine may promote SCC formation in OTRs by counteracting p53-dependent cellular senescence (95). Besides pharmacological immunosuppression, other tumor-promoting elements such as UV-induced DNA damage, human papillomaviruses, and tumor-stroma interactions have also been shown to contribute to SCC development in transplant recipients (92, 93).

Voriconazole is a second-generation triazole antifungal agent that is widely used for the treatment of invasive aspergillosis and candidiasis, particularly in immunocompromised patients. Since its FDA approval in 2002, chronic voriconazole therapy has been associated with an increased incidence of invasive cSCC in immunosuppressed patients including those who have undergone solid

Figure 5
Potential pathways that may be targeted by small molecules to treat AKs and cSCCs. Key signaling pathways driving cutaneous neoplasia are shown. Small molecules that can permeate the epidermis and target these signaling deficits may have therapeutic potential. Arrows denote stimulatory relationships and T-bars denote inhibitory relationships.
organ transplant or bone marrow transplant or experienced HIV infection or chronic granulomatous disease (97). A recent case-control study indicated that voriconazole is an independent risk factor for development of cSCC in lung transplant patients (98). The mechanism of voriconazole-induced cutaneous carcinogenesis is not known, but exposure to UV light is likely related, particularly given the drug-mediated photosensitivity exhibited by the patients (97). Voriconazole does not absorb light in the UV spectrum, but the primary metabolite, voriconazole N-oxide, can absorb UVA and UVB wavelengths. The drug is metabolized to the N-oxide form by cytochrome p450 enzymes located in the liver and in the gut epithelium. Keratinocytes also express many of these cytochrome p450 enzymes, raising the possibility of keratinoctye-mediated direct voriconazole N-oxidation (99). The signaling pathways activated by voriconazole or its N-oxide metabolite in keratinocytes are under investigation. Regular skin examinations and liberal use of sunscreens are recommended for patients taking voriconazole chronically.

**Therapeutic modalities and insights.** Current treatments for AKs involve topical and destructive modalities. The most commonly used topical agents to treat AKs are 5-FU, imiquimod (Aldara), and diclofenac (Solaraze). 5-FU is a chemotherapeutic agent that inhibits both RNA and DNA synthesis and targets dividing cells. AKs have a higher proportion of dividing cells than adjacent epidermis (100, 101). 5-FU has significant side effects, including prominent inflammation, ulceration, and even scarring; use of 5-FU is associated with a demonstrably lower quality of life for patients (102), and thus has many negative features as a first-line topical agent.

Imiquimod, a TLR7 agonist, acts through an immune-mediated mechanism that promotes prominent inflammation leading to elimination of AKs. This inflammation resembles psoriasis in its intensity and at the molecular level, and has been associated with induction of autoimmune reactions such as alopecia areata and vitiligo (103). Another common topical agent to treat AKs is diclofenac, a topical non-steroidal anti-inflammatory compound with an unclear mechanism of action on AKs. Recent studies using diclofenac and imiquimod showed therapeutic weaknesses associated with poor clearance rates and significant irritation (104). Overall, the most common topical agents used to treat AKs have significant negative features, including irritation, decreased quality of life, and limited efficacy. These data indicate a potential benefit to developing topical treatments that target pathophysiology of AKs without inducing skin irritation.

Recent innovations in medicine have resulted from the application of small molecules that correct signaling deficits in human neoplasia. Systemic administration of small molecules that can enhance p53 function, such as CP-31398, can inhibit UVB-induced carcinogenesis in mice (ref. 105 and Figure 5). Imatinib (Gleevec) and related compounds have been useful in treating neoplasia associated with increased tyrosine kinase activity, including chronic myelogenous leukemia and gastrointestinal stromal tumors with c-Kit mutations (refs. 106–109 and Figure 5). As described above, the systemic application of small molecules to target kinases driving neoplasia or to activate anti-oncogenic signaling pathways could be used to treat AKs and cSCC; identifying skin-permeable small molecules that target these pathways essential for lesion formation would be a first step. The murine models of skin cancer and xenografted genetically engineered human skin discussed in this Review are good screening tools for identifying potential topical agents that may be useful in treating AKs and cSCCs.

**Conclusions**

A number of pathophysiologic features of human cutaneous neoplasia have been elucidated using a wide range of experimental techniques. A more complete understanding of the molecular pathways that drive these cancers may yield new therapeutic insights for treating these common lesions.

**Acknowledgments**

This work is supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grant AR051380 to J.T. Seykora and grant P30-AR057257) and by the Department of Dermatology at the University of Pennsylvania.

Address correspondence to: John T. Seykora, University of Pennsylvania Medical School, 235a Clinical Research Building, 415 Curie Blvd., Philadelphia, Pennsylvania 19104, USA. Phone: 215.898.0170; Fax: 215.573.2143; E-mail: john.seykora@uphs.upenn.edu.


